Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10909238 | Leukemia Research | 2012 | 7 Pages |
Abstract
Large granular lymphocyte (LGL) leukemia is characterized by clonal expansion of antigen-activated cytotoxic T cells (CTL). Patients frequently exhibit seroreactivity against a human T-cell leukemia virus (HTLV) epitope, BA21. Aplastic anemia, paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome are bone marrow failure diseases that can also be associated with similar aberrant CTL activation (LGL-BMF). We identified a BA21 peptide that was specifically reactive with LGL leukemia sera and found significantly elevated antibody reactivity against the same peptide in LGL-BMF sera. This finding of shared seroreactivity in LGL-BMF conditions and LGL leukemia suggests that these diseases might share a common pathogenesis.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Susan Bell Nyland, Daniel J. Krissinger, Michael J. Clemente, Rosalyn B. Irby, Kendall Thomas Baab, Nancy Ruth Jarbadan, Lubomir Sokol, Eric Schaefer, Jason Liao, David Cuthbertson, Pearlie Epling-Burnette, Ronald Paquette, Alan F. List,